Practical strategies for hormone replacement therapy and risk of venous thromboembolism
- 1 April 1998
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 105 (4) , 376-379
- https://doi.org/10.1111/j.1471-0528.1998.tb10117.x
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Oral contraceptives and venous thromboembolismThe Lancet, 1997
- Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal WomenNew England Journal of Medicine, 1997
- Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogensThe Lancet, 1996
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- Prospective study of exogenous hormones and risk of pulmonary embolism in womenThe Lancet, 1996
- Resistance to activated protein C due to a factor V gene mutation: The most common inherited risk factor of thrombosisTrends in Cardiovascular Medicine, 1996
- Hormone replacement therapy may reduce high serum homocysteine in postmenopausal womenEuropean Journal of Clinical Investigation, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.BMJ, 1992
- Management of thrombophilia in pregnancyBlood Reviews, 1991